Milestone Scientific Commits to Regaining NYSE American Compliance Following Notification

Core Points - Milestone Scientific Inc. has received a notification from NYSE American regarding non-compliance with continued listing standards [1][2] - The company reported stockholders' equity of approximately $3.3 million and has experienced losses in each of its five most recent fiscal years [2] - The company is required to submit a compliance plan by November 7, 2025, to regain compliance by April 8, 2027 [3] Financial Position - The company does not meet the requirements of Section 1003(a)(ii) and Section 1003(a)(iii) of the NYSE American Company Guide [2] - The ongoing financial challenges are highlighted by the reported losses over the past five fiscal years [2] Management's Response - The CEO expressed confidence in the company's ability to meet NYSE American's continued listing standards through revenue growth initiatives and cost management [4] - The company remains focused on operational efficiency and delivering long-term value to shareholders [4][5] Business Operations - The receipt of the notification does not affect the company's day-to-day operations or its reporting obligations with the SEC [4] - The company's common stock will continue to trade under the symbol "MLSS" while it works on compliance [4] Company Overview - Milestone Scientific Inc. specializes in developing computerized drug delivery instruments aimed at providing painless and precise injections [6] - The company utilizes its proprietary DPS Dynamic Pressure Sensing Technology to enhance injection safety and comfort [6]